Detection and Quantification of HspX Antigen in Sputum Samples Using Plasmonic Biosensing: Toward a Real Point-of-Care (POC) for Tuberculosis Diagnosis

Peláez, E. Cristina; Estévez, M.‐Carmen; Mongui, Alvaro; Menéndez, M-Carmen; Toro-Rueda, Carlos; Herrera-Sandoval, Oscar L; Robledo, Jaime; García, María Jesús García; Portillo, Patricia Del; Lechuga, Laura M.

doi:10.1021/acsinfecdis.9b00502

Cited by 35 publications

(27 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They have been widely used because of their short detection time, fast analysis speed, and flexible portability. As a routine laboratory microbial detection technology, biochemical technology is used in combination with biosensors for the preliminary treatment of samples (Peláez et al, 2020). On the basis of the specific combination of antibody and antigen, immune technology introduces biosensors to construct an immunosensor, which has been extensively used in the detection of airborne microorganisms (Shen et al, 2009;Mavrikou et al, 2020).…”

Section: Airborne Microorganism Detection Methodsmentioning

confidence: 99%

“…The optical biosensor is a biosensor that converts the signal of the detected object into a detectable optical signal. Optical biosensors mainly utilize the properties of light, such as fluorescence (Wu et al, 2019), surface plasma resonance (SPR) (Peláez et al, 2020) and colorimetric (Briceno et al, 2019) sensors. The fluorescence sensor uses the unique photophysical properties of fluorescent nanomaterials for labeling and detection of microorganisms (Zheng et al, 2019).…”

Section: Optical Biosensormentioning

confidence: 99%

“…Peláez et al used the SPR biosensor for the direct and label-free detection of the HspX recombinant antigen of MTB. Moreover, their process involved simple pretreatment of sputum specimens without any additional amplification steps, with a detection limit of 0.63 ng/mL (Peláez et al, 2020). Briceno et al used a colorimetric biosensor to complete detection within 20 min and can reach the sensitivity level of the culture method (Briceno et al, 2019).…”

Section: Optical Biosensormentioning

confidence: 99%

See 2 more Smart Citations

Advances in airborne microorganisms detection using biosensors: A critical review

Wang

et al. 2021

Front. Environ. Sci. Eng.

View full text Add to dashboard Cite

Humanity has been facing the threat of a variety of infectious diseases. Airborne microorganisms can cause airborne infectious diseases, which spread rapidly and extensively, causing huge losses to human society on a global scale. In recent years, the detection technology for airborne microorganisms has developed rapidly; it can be roughly divided into biochemical, immune, and molecular technologies. However, these technologies still have some shortcomings; they are time-consuming and have low sensitivity and poor stability. Most of them need to be used in the ideal environment of a laboratory, which limits their applications. A biosensor is a device that converts biological signals into detectable signals. As an interdisciplinary field, biosensors have successfully introduced a variety of technologies for bio-detection. Given their fast analysis speed, high sensitivity, good portability, strong specificity, and low cost, biosensors have been widely used in environmental monitoring, medical research, food and agricultural safety, military medicine and other fields. In recent years, the performance of biosensors has greatly improved, becoming a promising technology for airborne microorganism detection. This review introduces the detection principle of biosensors from the three aspects of component identification, energy conversion principle, and signal amplification. It also summarizes its research and application in airborne microorganism detection. The new progress and future development trend of the biosensor detection of airborne microorganisms are analyzed.

show abstract

Section: Airborne Microorganism Detection Methodsmentioning

confidence: 99%

Section: Optical Biosensormentioning

confidence: 99%

Section: Optical Biosensormentioning

confidence: 99%

See 1 more Smart Citation

Advances in airborne microorganisms detection using biosensors: A critical review

Wang

et al. 2021

Front. Environ. Sci. Eng.

View full text Add to dashboard Cite

show abstract

“…Compared to the electrochemical mechanism, the photonic biosensors can achieve a high signal-to-noise ratio [ 98 , 99 ]. Several studies have demonstrated the applications of photonics techniques for POC detection and diagnosis [ 100 , 101 ]. Belushkin et al [ 72 ] investigated the early diagnosis of sepsis by using a compact photonic detection setup.…”

Section: Recent Advances In Poc Technologies For Covid-19mentioning

confidence: 99%

Emerging point-of-care biosensors for rapid diagnosis of COVID-19: current progress, challenges, and future prospects

Rasmi

Khan

et al. 2021

Anal Bioanal Chem

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) pandemic is currently a serious global health threat. While conventional laboratory tests such as quantitative real-time polymerase chain reaction (qPCR), serology tests, and chest computerized tomography (CT) scan allow diagnosis of COVID-19, these tests are time-consuming and laborious, and are limited in resource-limited settings or developing countries. Point-of-care (POC) biosensors such as chip-based and paper-based biosensors are typically rapid, portable, cost-effective, and user-friendly, which can be used for COVID-19 in remote settings. The escalating demand for rapid diagnosis of COVID-19 presents a strong need for a timely and comprehensive review on the POC biosensors for COVID-19 that meet ASSURED criteria: Affordable, Sensitive, Specific, User-friendly, Rapid and Robust, Equipment-free, and Deliverable to end users. In the present review, we discuss the importance of rapid and early diagnosis of COVID-19 and pathogenesis of COVID-19 along with the key diagnostic biomarkers. We critically review the most recent advances in POC biosensors which show great promise for the detection of COVID-19 based on three main categories: chip-based biosensors, paper-based biosensors, and other biosensors. We subsequently discuss the key benefits of these biosensors and their use for the detection of antigen, antibody, and viral nucleic acids. The commercial POC biosensors for COVID-19 are critically compared. Finally, we discuss the key challenges and future perspectives of developing emerging POC biosensors for COVID-19. This review would be very useful for guiding strategies for developing and commercializing rapid POC tests to manage the spread of infections.

show abstract

“…concentration). Our biosensor device has previously demonstrated its potential for clinical diagnostics in several areas, 35,38 including infectious diseases 34 and also for the direct detection of antibodies in human serum, 33,36 enabling a one-step, label-free, and sensitive and reliable detection. These features are crucial to develop a fast test with response times below 15-20 minutes (thanks to the noneed of secondary reagents or further signal amplification steps), and with the potential of providing quantitative information (i.e., the concentration range of antibodies in serum).…”

Section: Biosensor Assay Development and Analytical Characterizationmentioning

confidence: 99%

Label-Free Plasmonic Biosensor for Rapid, Quantitative, and Highly Sensitive COVID-19 Serology: Implementation and Clinical Validation

Calvo-Lozano¹,

Sierra²,

Soler³

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Serological tests are essential for the control and management of COVID-19 pandemic, not only for current and historical diagnostics but especially for surveillance, epidemiological, and acquired immunity studies. Clinical COVID-19 serology is routinely performed by enzymatic or chemiluminescence immunoassays (i.e., ELISA or CLIA), which provide good sensitivities at the expense of relatively long turnaround times and specialized laboratory settings. Rapid serological tests, based on lateral flow assays, have also been developed and widely commercialized, but they suffer from limited reliability due to relatively low sensitivity and specificity. We have developed and validated a direct serological biosensor assay employing proprietary technology based on Surface Plasmon Resonance (SPR). The biosensor offers a rapid -less than 15 min- identification and quantification of SARS-CoV-2 antibodies directly in clinical samples, without the need of any signal amplification. The portable plasmonic biosensor device employs a custom-designed multi-antigen sensor biochip, combining the two main viral antigens (RBD peptide and N protein), for simultaneous detection of human antibodies targeting both antigens. The SPR serology assay reaches detection limits in the low ng mL-1 range employing polyclonal antibodies as standard, which are well below the commonly detected antibody levels in COVID-19 patients. The assay has also been implemented employing the first WHO approved anti-SARS-CoV-2 immunoglobulin standard. We have carried out a clinical validation with COVID-19 positive and negative samples (n=120) that demonstrates the excellent diagnostic sensitivity (99%) and specificity (100%). This positions our biosensor device as an accurate, robust, and easy-to-use diagnostics tool for rapid and reliable COVID-19 serology to be employed both at laboratory and decentralized settings for the management of COVID-19 patients and for the evaluation of immunological status during vaccination, treatment or in front of emerging variants.<br>

show abstract

Detection and Quantification of HspX Antigen in Sputum Samples Using Plasmonic Biosensing: Toward a Real Point-of-Care (POC) for Tuberculosis Diagnosis

Cited by 35 publications

References 55 publications

Advances in airborne microorganisms detection using biosensors: A critical review

Advances in airborne microorganisms detection using biosensors: A critical review

Emerging point-of-care biosensors for rapid diagnosis of COVID-19: current progress, challenges, and future prospects

Label-Free Plasmonic Biosensor for Rapid, Quantitative, and Highly Sensitive COVID-19 Serology: Implementation and Clinical Validation

Contact Info

Product

Resources

About